Thermal denaturation:: A method to rank slow binding, high-affinity p38α MAP kinase inhibitors

被引:47
作者
Kroe, RR
Regan, J
Proto, A
Peet, GW
Roy, T
Landro, LD
Fuschetto, NG
Pargellis, CA
Ingraham, RH
机构
[1] Boehringer Ingelheim Pharmaceut Inc, Dept Immunol & Inflammat, Ridgefield, CT 06877 USA
[2] Boehringer Ingelheim Pharmaceut Inc, Dept Med Chem, Ridgefield, CT 06877 USA
[3] Univ Autonoma Guadalajara, Guadalajara 45110, Jalisco, Mexico
[4] Boehringer Ingelheim Pharmaceut Inc, Dept Biometr & Data Management, Ridgefield, CT 06877 USA
[5] Bristol Cent High Sch, Bristol, CT 06010 USA
关键词
D O I
10.1021/jm030120s
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
It has been reported that the diaryl urea class of p38alpha inhibitors binds to p38 map kinase with both high affinity and slow binding kinetics (Pargellis et al. Nat. Struct. Biol. 2002, 9, 268-272). The slow binding kinetics of this class of inhibitors is believed to be the result of binding to an allosteric pocket adjacent to the p38alpha active site. The use of traditional kinetic and equilibrium methods to measure the binding affinity of this class of compounds has created many challenges for determination of structure-activity relationships (SAR). The thermal denaturation method provides a means of measuring high-affinity interactions. In this paper, the method of thermal denaturation will be described as it has been applied to the diaryl urea class of p38 map kinase inhibitors.
引用
收藏
页码:4669 / 4675
页数:7
相关论文
共 16 条
[1]  
Bevington R., 1969, DATA REDUCTION ERROR
[2]   STUDY OF STRONG TO ULTRATIGHT PROTEIN INTERACTIONS USING DIFFERENTIAL SCANNING CALORIMETRY [J].
BRANDTS, JF ;
LIN, LN .
BIOCHEMISTRY, 1990, 29 (29) :6927-6940
[3]   Protein kinase inhibitors: emerging pharmacophores 1997-2000 [J].
Dumas, J .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2001, 11 (03) :405-429
[4]  
Fuller W. A., 2009, Measurement error models
[5]  
HINZ HJ, 1986, METHOD ENZYMOL, V130, P59
[6]   High-density miniaturized thermal shift assays as a general strategy for drug discovery [J].
Pantoliano, MW ;
Petrella, EC ;
Kwasnoski, JD ;
Lobanov, VS ;
Myslik, J ;
Graf, E ;
Carver, T ;
Asel, E ;
Springer, BA ;
Lane, P ;
Salemme, FR .
JOURNAL OF BIOMOLECULAR SCREENING, 2001, 6 (06) :429-440
[7]   Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site [J].
Pargellis, C ;
Tong, L ;
Churchill, L ;
Cirillo, PF ;
Gilmore, T ;
Graham, AG ;
Grob, PM ;
Hickey, ER ;
Moss, N ;
Pav, S ;
Regan, J .
NATURE STRUCTURAL BIOLOGY, 2002, 9 (04) :268-272
[8]   An autosampling differential scanning calorimeter instrument for studying molecular interactions [J].
Plotnikov, V ;
Rochalski, A ;
Brandts, M ;
Brandts, JF ;
Williston, S ;
Frasca, V ;
Lin, LN .
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2002, 1 (01) :83-90
[9]   Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical candidate [J].
Regan, J ;
Breitfelder, S ;
Cirillo, P ;
Gilmore, T ;
Graham, AG ;
Hickey, E ;
Klaus, B ;
Madwed, J ;
Moriak, M ;
Moss, N ;
Pargellis, C ;
Pav, S ;
Proto, A ;
Swinamer, A ;
Tong, L ;
Torcellini, C .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (14) :2994-3008
[10]   Structure-activity relationships of the p38α MAP kinase inhibitor 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]urea (BIRB 796) [J].
Regan, J ;
Capolino, A ;
Cirillo, PF ;
Gilmore, T ;
Graham, AG ;
Hickey, E ;
Kroe, RR ;
Madwed, JR ;
Moriak, M ;
Nelson, R ;
Pargellis, CA ;
Swinamer, A ;
Torcellini, C ;
Tsang, M ;
Moss, N .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (22) :4676-4686